Tag Archives: Ozempic

GLP-1 receptor agonists have transformed the treatment of type 2 diabetes, but their effects on gastrointestinal motility remain an important clinical consideration. Opioids can also slow gastrointestinal function, raising an obvious question: what happens when patients need both? New research examining GLP-1 and opioid interactions suggests that opioid choice may …

GLP-1 receptor agonists have transformed type 2 diabetes and obesity treatment, but a rare vision safety signal deserves clinicians’ attention. Emerging evidence has raised concerns about a potential NAION risk with GLP-1 therapy, particularly with semaglutide (Ozempic, Rybelsus, and Wegovy). Non-arteritic anterior ischemic optic neuropathy (NAION) can cause sudden, usually …

Could a stool sample someday help clinicians choose a diabetes medication before writing the prescription? Emerging research into gut biomarkers in diabetes is moving that possibility closer to clinical reality. Rather than simply cataloging which bacteria live in the intestine, researchers are examining microbial genes, stool-derived metabolites, and functional signatures …

The rise of highly effective GLP-1 receptor agonists and dual incretin therapies has transformed obesity treatment. Medications such as semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) are helping patients achieve levels of weight loss that were previously difficult to attain without bariatric surgery. However, as clinicians celebrate these advances, a …

A patient loses 30 pounds, lowers their A1C, and improves their blood pressure within months of starting a GLP-1 medication. Stories like these are hard to ignore, and they have helped fuel growing enthusiasm around drugs like Ozempic, Wegovy, and Mounjaro. Yet as prescriptions continue to expand beyond high-risk diabetes …

Dermatologic reactions linked to GLP-1 therapy are gaining attention as the use of glucagon-like peptide-1 receptor agonists continues to expand in diabetes and obesity care. While injection-site irritation is well recognized, clinicians are increasingly observing broader skin changes in patients treated with semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), and tirzepatide …

The expanding use of GLP-1 receptor agonists for type 2 diabetes and obesity has transformed metabolic care. However, growing awareness of the potential gallbladder risks associated with GLP-1 therapy has prompted clinicians to take a closer look at hepatobiliary safety. Rapid weight loss and altered bile composition during treatment may …

Cardiovascular outcomes often dominate discussions about GLP-1 receptor agonists, but what about nerve health? Growing interest in GLP-1 diabetic neuropathy reflects a broader shift toward understanding microvascular complications beyond heart disease. While medications such as semaglutide (Ozempic), dulaglutide (Trulicity), and liraglutide (Victoza) have proven cardiovascular benefits, their potential influence on …

The link between metabolism and reproduction is gaining attention, especially as questions about GLP-1 therapy and male fertility begin to surface in clinical practice. For years, male fertility evaluations focused mainly on hormones and anatomy. However, what if the root problem starts with metabolic health? Obesity and insulin resistance are …

Patients using GLP-1 receptor agonists are reporting something unexpected: less joint and musculoskeletal pain. As interest grows in how GLP-1 therapies may affect chronic pain, clinicians are asking an important question. Are these improvements simply the result of weight loss, or do GLP-1 medications have direct anti-inflammatory and neuromodulatory effects? …